Bridgeway Capital Management’s HCW Biologics HCWB Stock Holding History

Bridgeway Capital Management’s Portfolio HCWB Stock Details HCWB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-145	Closed	-$15.5K	–	1210
2024 Q4	$15.5K	Sell	145 -208	-59%	-$24.3K	﹤0.01%	1187
2024 Q3	$45.7K	Hold	353	–	–	﹤0.01%	1217
2024 Q2	$54.8K	Hold	353	–	–	﹤0.01%	1206
2024 Q1	$141K	Hold	353	–	–	﹤0.01%	1164
2023 Q4	$104K	Buy	353 +9	+3%	+$3.07K	﹤0.01%	1234
2023 Q3	$158K	Hold	344	–	–	﹤0.01%	1137
2023 Q2	$179K	Hold	344	–	–	﹤0.01%	1159
2023 Q1	$114K	Buy	344 +41	+14%	+$17.8K	﹤0.01%	1210
2022 Q4	$139K	Hold	303	–	–	﹤0.01%	1165
2022 Q3	$166K	Hold	303	–	–	﹤0.01%	1172
2022 Q2	$160K	Buy	303 +67	+28%	+$37.6K	﹤0.01%	1138
2022 Q1	$155K	Buy	236 +42	+22%	+$22.4K	﹤0.01%	1208
2021 Q4	$108K	Buy	+194	New	+$132K	﹤0.01%	1211

Other funds holding HCWB

APP

Avantax Planning Partners Dubuque, Iowa $4.02B AUM 20% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

PIM

Pullen Investment Management Bradenton, Florida $216M AUM 32.94% 1-Year Est. Return

JWCA

J.W. Cole Advisors Tampa, Florida $5.83B AUM 32.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AWM

AE Wealth Management Topeka, Kansas $18.5B AUM 19.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPIM

Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return

Bridgeway Capital Management's HCWB Position: Q1 2025 in Review

Bridgeway Capital Management sold out of HCW Biologics (HCWB) in Q1 2025, closing a stake of 145 shares — an estimated $15.5K sold.

Bridgeway Capital Management first reported a position in HCWB in Q4 2021 and held it in 13 quarters. The position peaked at $179K in Q2 2023. 14 funds tracked by Wall St. Rank hold HCWB as of Q1 2025.

Bridgeway Capital Management reported no remaining HCW Biologics position as of Q1 2025 after selling out during the quarter.
Bridgeway Capital Management sold 145 HCW Biologics shares in Q1 2025, an estimated $15.5K.
Bridgeway Capital Management first reported a position in HCW Biologics in Q4 2021 and held it in 13 quarters.
Bridgeway Capital Management's HCW Biologics position peaked at $179K in Q2 2023.
14 funds tracked by Wall St. Rank held HCW Biologics as of Q1 2025.

Based on Bridgeway Capital Management's 13F filing for Q1 2025, filed 15 May 2025.